Furthermore, our results showing BRCA1-BRCT function is required for the rapid alkylation-induced degradation of BRCA1-SPT5 and RNAPII suggests that chemotherapeutic treatments utilizing alkylating agents may be clinically effective for treating breast cancers in which BRCA1-mediated degradation is defective. Here, BRCA1 is linked to breast carcinoma.